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 Chapter 7 
 Host-Derived Biomarkers for Risk Assessment of Invasive 
Fungal Diseases 
 Cristina  Cunha ,  Samuel  M.  Gonçalves , and  Agostinho  Carvalho 
 Abstract 
 Invasive fungal diseases are major complications associated with the treatment of hematologic malignan-
cies. The integration of host-derived biomarkers into clinical processes to predict the risk and progression 
of fungal disease is a promising approach in immunocompromised patients. Recent insights into human 
antifungal immunity have highlighted the remarkable infl uence of host genetics in modulating susceptibil-
ity to infection. In this chapter, we describe protocols to examine human genetic variation and to assess its 
functional consequences using the pattern recognition receptor PTX3 as an example. 
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1  Introduction 
 Invasive  fungal diseases, particularly invasive  aspergillosis (IA), are 
major complications associated with the treatment of hematologic 
malignancies [ 1 ]. Vaccines are not available, and despite notewor-
thy recent developments in diagnostic and therapeutic approaches, 
these diseases remain associated with unacceptable mortality rates 
[ 2 ,  3 ]. Concerns over excessive prescription of antifungal drugs 
and the remarkable burden these diseases convey to the healthcare 
systems are inspiring a shift from universal prophylaxis to  risk strat-
ifi cation and preemptive approaches. Recent evidence continues to 
highlight the complexity of the multiple fungal-sensing immune 
systems and the remarkable infl uence of the host genetics in the 
ability to control infection risk and its progression. As a result of 
our improved understanding of the host–fungus  interaction , sev-
eral relevant target genes (and associated genetic variants) with the 
potential to be exploited in future personalized  medical interven-
tions in high-risk settings based on individual genetic risk have 
been identifi ed. 
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 Chronic granulomatous disease and autosomal-dominant 
hyper-IgE syndrome (AD-HIES) are the most common examples 
of primary immunodefi ciencies typically associated with suscepti-
bility to IA [ 4 ]. These severe immune defi ciencies with monogenic 
inheritance are usually limited to a very small number of individu-
als or families, but the  identifi cation of genetic defects is very infor-
mative on immune defense mechanisms. For most individuals 
however, genetic propensity to fungal disease has a polygenic 
inheritance, acting in concert with other clinical predisposing vari-
ants such as chemotherapy-induced neutropenia. Our increasing 
ability to analyze human variability at the  DNA level has made pos-
sible the identifi cation of several host genetic variants amenable to 
use in the categorization of patients with a high risk of infection 
and to target antifungal therapy (reviewed in [ 5 ,  6 ]). However, the 
clinical translation of this active fi eld of research is still limited, 
mostly due to the heterogeneity of cohorts, sample size, case and 
control selection bias, and statistical misconceptions. 
 Among the most encouraging examples reported to date, a 
donor haplotype in Toll-like receptor 4 (TLR4) underlying a 
delayed T cell and natural killer T cell immune reconstitution [ 7 ] 
has been disclosed as an important risk factor for developing IA in 
recipients of allogeneic hematopoietic stem cell transplantation 
(HSCT) [ 8 ]. In addition, TLR4 variants have been previously 
linked with chronic aspergillosis in immunocompetent individuals 
[ 9 ] and fungal colonization in HSCT recipients [ 10 ]. However, 
and since the fungal ligand (or the host-derived molecule released 
in response to  fungal infection ) for TLR4 remains debated, uncov-
ering the exact mechanism(s) through which TLR4 defi ciency 
impacts  antifungal immunity is required to strengthen the prog-
nostic signifi cance of its genetic variation. 
 It is noteworthy that, in addition to TLR4, genetic variation in 
other TLRs has also been proposed to infl uence the risk of IA. For 
example, a regulatory variant decreasing the expression of TLR3 in 
dendritic cells was found to impair the recognition of fungal nucleic 
acids and to compromise the effi cient priming of protective mem-
ory CD8+ T cell responses, thereby rendering HSCT recipients 
more prone to develop IA [ 11 ]. Ultimately, the evaluation of regu-
latory variation impacting adaptive immunity might help to 
enhance the discriminatory potential of recent immunodiagnostic 
strategies based on the evaluation of fungal-specifi c adaptive 
immune responses [ 12 ]. Of interest, damage perception is coupled 
with pathogen-sensing pathways (especially intracellular TLRs) to 
restrain infl ammation in experimental aspergillosis [ 13 ]. Therefore, 
it is not surprising that genetic variants determining a hyperactiva-
tion in danger signaling axes, and presumably underlying exuber-
ant infl ammatory responses, were also found to increase the risk for 
 IA [ 14 ]. Finally, other examples include genetic variants in TLR1 
and TLR6 [ 15 ], and TLR5 [ 16 ], but further studies are warranted 
to defi nitely assure their predictive potential for fungal disease. 
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 Dectin-1 defi ciency has consistently been reported to contrib-
ute to susceptibility to IA [ 17 – 19 ]. In particular, a stop codon 
polymorphism in Dectin-1 ( CLEC7A ) compromising the surface 
expression of the receptor in myeloid cells and downstream cyto-
kine production in response to  fungal infection [ 20 ] signifi cantly 
increased the risk of IA in HSCT recipients [ 18 ]. The fact that 
Dectin-1 defi ciency in both transplant counterparts synergized 
towards risk of IA highlighted for the fi rst time the pivotal contri-
bution of non-hematopoietic Dectin-1 in  antifungal immunity . 
The prominent biological plausibility of this association suggests 
Dectin-1 as an attractive candidate not only in  risk stratifi cation 
measures but also in immunotherapeutic strategies aiming at coun-
tering the defective Dectin-1 function. 
 Numerous positive associations between genetic variants in 
cytokine and chemokine genes and risk of IA have also been 
reported [ 21 – 26 ]. Most of these initial reports were however 
largely underpowered and performed in poorly characterized 
cohorts, thereby precluding defi nite conclusions about genetic 
variants affecting cytokine production in the context of IA. There 
are however some exceptions that assume particular relevance 
given the robust study design and functional validation [ 22 ,  27 ]. 
Among the exceptions, a haplotype in C-X-C motif ligand 10 
(CXCL10) was mechanistically correlated to a defi cient expression 
of this chemokine in dendritic cells and, accordingly, high levels of 
CXCL10 were also more frequently observed among patients sur-
viving IA compared to unaffected controls [ 22 ]. More recently, 
variants in the genes encoding for IL-1β and beta-defensin 1 
(DEFB1) were reported to increase the risk of IA in solid organ 
transplant recipients, supposedly by impairing fungal-induced pro-
infl ammatory cytokine secretion by mononuclear cells [ 27 ]. 
 Next-generation  sequencing technologies now provide excit-
ing possibilities to pin down essential steps in the host-fungus 
 interaction at a level of complexity previously unanticipated. The 
fi rst genome-wide association studies (GWAS) exploring host sus-
ceptibility to IA are underway and are expected to provide unbi-
ased insights into the genetic defects contributing to development 
of IA. The plausibility of these approaches has been recently dem-
onstrated in invasive fungal diseases, in which functional genomics 
analyses have allowed the  identifi cation of new important players 
controlling susceptibility to candidemia [ 28 ,  29 ]. Finally, genetic 
analysis of gene expression represents another powerful approach 
enabling insights into the human genomic landscape by generating 
expression maps that might be revealed extremely useful for the 
functional interpretation of noncoding variants likely to arise from 
ongoing genome-wide initiatives [ 30 ]. 
 A number of alternative strategies using  mouse models of 
infection as a starting point have also been employed to defi ne 
candidate genes involved in susceptibility to IA [ 31 ,  32 ]. Genetic 
mapping analysis of survival data of animals subjected to experi-
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mental infection led to the  identifi cation of a non-synonymous 
polymorphism in human plasminogen (PLG), a regulatory mole-
cule with opsonic properties, as an important modulator of suscep-
tibility to IA in humans [ 32 ]. Genetic defi ciency of additional 
molecules with opsonic activity—e.g., mannose-binding lectin 
(MBL) [ 33 ] and the long pentraxin 3 (PTX3) [ 34 ]—has also been 
disclosed as a major determinant of susceptibility to IA, pointing to 
a key contribution of the innate humoral arm to an adequate acti-
vation of protective antifungal  immune responses. This is corrobo-
rated by the validation of the association of a PTX3 haplotype and 
increased risk of IA in two independent, high-powered genetic 
association studies [ 34 ,  35 ]. The involved haplotype was found to 
compromise the alveolar availability of  PTX3 and, at a cellular 
level, its expression during the developmental programming of 
neutrophil precursors in the bone marrow, leading to defective 
antifungal effector mechanisms of newly reconstituted neutrophils 
[ 34 ]. Importantly, this association was also recently replicated in 
recipients of lung transplant [ 36 ], highlighting a potential applica-
bility of these markers in predicting infection across patients with 
intrinsically different predisposing conditions. Of interest, the alve-
olar levels of  PTX3 have been demonstrated to discriminate micro-
biologically confi rmed pneumonia in mechanically ventilated 
patients [ 37 ]. Given that these levels vary individually according to 
host genotypes [ 34 ], we can envisage the quantifi cation of PTX3 in 
bronchoalveolar  lavage fl uids as a complementary surveillance 
measure in addition to the currently available diagnostic approaches. 
Finally, the fact that exogenous administration of PTX3 is able to 
revert the genetic defect  in vitro [ 34 ] further highlights the poten-
tial of PTX3-based immunotherapies to treat (or prevent) IA [ 38 ]. 
 Although the overall weight of the antifungal  immune response 
is certainly driven by adding effects of single genetic factors and 
their complex interactions with clinical immune dysfunctions, 
 PTX3 represents the most robust genetic marker identifi ed to date. 
These consistent fi ndings are expected to lay the foundations for 
well-designed prospective trials ultimately endorsing PTX3-based 
genetic testing in  risk stratifi cation approaches for IA. In this chap-
ter, we will use PTX3 as an example to describe protocols to assess 
genetic variation in PTX3 associated with susceptibility to IA, and 
to evaluate the associated functional consequences in circulating 
neutrophils from patients at-risk. 
2  Materials 
 Prepare all solutions using ultrapure water and cell- culture grade 
reagents. Prepare and store all reagents at room temperature 
(unless indicated otherwise). Carefully follow all waste disposal 
regulations when disposing of human waste materials. 
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  1.  Quick-gDNA ™ MiniPrep Kit (Zymo Research). 
  1.  KASP™ Assay Mix for the rs2305619, rs3816527, and 
rs1840680 SNPs in  PTX3 and KASP™ Master Mix (LGC 
Genomics). 
  1.  Histopaque 1077 (Sigma-Aldrich). 
  2.  NaCl 0.2, 0.9, and 1.6 %. 
  3.  Dextran T-500 from Alfa Aesar (cat #: J63702) 3 % in 0.9 % 
NaCl (dextran/saline solution). 
  4.  PBS: NaCl 137 mM, KCl 2.7 mM, Na 2 HPO 4 8.1 mM, 
KH 2 PO 4 1.5 mM, pH 7.2–7.4, 0.2 μm fi ltered. 
  1.  Neutrophil lysis buffer: Tris–HCl 10 mM, EDTA 5 mM, NP40 
1 %, and 1× protease inhibitors. 
  1.  ELISA to  detect human PTX3, for example the Pentraxin 3/
TSG-14 DuoSet ELISA (R&D systems). 
  2.  PBS (prepared as above). 
  3.  Wash buffer: Tween 20 0.05 % in PBS, pH 7.2–7.4. 
  4.  Reagent diluent: bovine serum albumin (BSA) 1 % in PBS, pH 
7.2–7.4 (stored at 4 °C). 
  5.  Substrate solution: 1:1 mixture of color reagent A (H 2 O 2 ) and 
color reagent B (tetramethylbenzidine). 
  6.  Stop solution: H 2 SO 4 2 N. 
  1.  Live conidia from  Aspergillus fumigatus . 
  2.  Fluorescein isothiocyanate (FITC) (Sigma-Aldrich). 
  3.  RPMI Medium 1640 (Thermo Fisher Scientifi c). 
  4.  Sabouraud Dextrose agar (BD Difco ™ ). 
3  Methods 
 For the purpose of this chapter, genetic variants in  PTX3 are given 
as examples of common variants that have been described to infl u-
ence the risk of IA; however, these can be replaced with other 
known and novel genetic markers. The methods addressing the 
functional consequences of these variants and described below 
have been verifi ed in human circulating neutrophils. 
 Reagents used to isolate genomic DNA are part of the Quick- 
gDNA ™ MiniPrep Kit. By using the innovative Zymo-Spin™ 
Column technology, this kit yields highly purifi ed RNA-free DNA, 
bypassing the need for RNase A treatment and excluding the use 
2.1  DNA Isolation
2.2  Single Nucleotide 
Polymorphism ( SNP ) 
Genotyping
2.3  Neutrophil 
Isolation
2.4  Neutrophil Lysis
2.5  ELISA for  PTX3 
2.6  Assessment 
of Neutrophil Effector 
Functions
3.1  Isolation 
of Genomic DNA 
from Peripheral Blood
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of proteinase K and organic denaturants, thereby ensuring high 
quality for sensitive downstream applications, including  SNP  anal-
ysis . In addition, all reagents are compatible with commonly used 
anticoagulants (i.e., EDTA, heparin, citrate) in blood drawing pro-
cedures. Additional equipment required includes a microcentri-
fuge and a vortex. 
  1.  Add 400 μL of lysis buffer to 100 μL of whole blood (4:1). 
Mix thoroughly by vortexing and allow the mixture to rest for 
5–10 min at room temperature ( see  Note  1 ). 
  2.  Transfer the mixture to a Zymo-Spin ™ column in a collection 
tube and centrifuge at 10,000 ×  g for 1 min. 
  3.  Wash the column with 200 μL of DNA pre-wash buffer and 
centrifuge as before. 
  4.  Add 500 μL of DNA wash buffer to the column and centrifuge 
as before. 
  5.  Elute the DNA in 50 μL of elution buffer and collect the puri-
fi ed DNA in a clean microcentrifuge tube ( see  Note  2 ). 
  6.  Determine the concentration of DNA in each sample by light 
spectrophotometry (e.g., NanoDrop) using the elution buffer 
as blank. 
 The Kompetitive Allele-Specifi c  PCR (KASPar) chemistry (LGC 
Genomics) is hereafter used as an example of a commercial on- 
demand assay to perform genotyping. This kit contains a KASP™ 
Assay Mix that is specifi c to the SNPs under analysis and consists of 
two competitive, allele-specifi c forward primers and one common 
reverse primer. Each forward primer incorporates an additional tail 
sequence that corresponds with one of two universal fl uorescent 
resonance energy transfer (FRET) cassettes (FAM and HEX) pres-
ent in the KASP™ Master Mix. This mix also includes the ROX™ 
passive reference dye, Taq polymerase, free nucleotides, and MgCl 2 
in an optimized buffer solution.
  1.  Vortex thoroughly all the components of the KASPar assay 
prior to use. 
  2.  Dispense 5 μL of each DNA sample onto a qPCR-compatible 
96-well plate ( see  Note  3 ). Make sure to include at least three 
non-template controls (NTC) containing ultrapure water. 
  3.  Prepare a master mix containing 5 μL of 2× reaction mix and 
0.14 μL of the primer mix for each sample to be  analyzed . 
  4.  Add 5 μL of the master mix to each DNA and NTC well. 
  5.  Seal the 96-well plate carefully and run the qPCR in a compat-
ible instrument according to the following thermal profi le 
( see  Notes  4 and  5 ).
3.2  Genotyping 
of  PTX3 SNPs
Cristina Cunha et al.
159
 Holding stage  Cycling stage (10 cycles)  Cycling stage (32 cycles) 
 Post-PCR read 
(holding stage) 
 94 °C 
 15 min 
 94 °C 
 20 s 
 61 °C 
 60 s 
 (−0.6 °C/cycle) 
 96 °C 
 20 s 
 55 °C 
 60 s 
 25 °C 
 60 s 
  6.  Perform the allelic discrimination by reading fl uorescence at 
25 °C (Fig.  1 ).
  7.  In the event clear genotyping clusters are not observed, the 
plate should be thermally cycled further (three additional 
cycles of 20 s at 94 °C and 60 s at 57 °C) and read again at 
25 ° C . 
  1.  Dilute the collected whole blood at a 1:4 proportion with 
0.9 % NaCl. 
  2.  Layer 10 mL of Histopaque 1077 beneath the diluted whole 
blood using a pipette or a syringe ( see  Note  6 ). 
  3.  Centrifuge at 400 ×  g for 40 min at 20 °C without brake 
( see  Note  7 ). 
  4.  Aspirate and discard the supernatant and resuspend the granu-
locyte/red blood cell (RBC) pellet in 20 mL of PBS. 
  5.  Add an equal volume of dextran/saline solution, mix and incu-
bate in the upright position for approximately 30 min at room 
temperature. 
3.3  Isolation 
of Circulating 
Neutrophils
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 Fig. 1  Typical allelic discrimination plot obtained for the rs2305619  SNP in the 
 PTX3 gene. Genotyping was performed using KASPar chemistry in a 7500 Fast 
qPCR  system  (Applied Biosystems) 
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  6.  Aspirate and save the leukocyte-rich plasma (upper layer) using 
a pipette. 
  7.  Pellet cells from the plasma by centrifuging at 250 ×  g for 
10 min at 4 °C ( see  Note  8 ). 
  8.  To remove residual RBC, subject cells to hypotonic lysis by 
resuspending the pellet in 20 mL of cold 0.2 % NaCl for exactly 
30 s. 
  9.  Restore isotonicity by adding 20 mL of ice-cold 1.6 % NaCl. 
  10.  Centrifuge at 250 ×  g for 6 min at 4 °C and discard the super-
natant. Repeat steps 8 and 9 until the cell pellet appears free of 
 RBC . 
  11.  Resuspend cells in ice-cold PBS and determine cell concentra-
tion by counting in a Neubauer chamber. 
  1.  Transfer 10 6 neutrophils into an Eppendorf tube and remove 
the supernatant by centrifuging at 250 ×  g for 6 min at 4 °C. 
  2.  Add 200 μL of lysis buffer and incubate 5 min on ice. 
  3.  Collect the cell lysate by centrifugation at 12,000 ×  g for 15 min 
at 4 °C. 
  4.  Store at −80 °C until the determination of intracellular  PTX3 
by  ELISA . 
 All reagents from the ELISA kit for PTX3 should be brought to 
room temperature before use and the reconstituted components 
should be allowed to sit for at least 15 min with gentle agitation. 
Working dilutions should be prepared according to the manufac-
turer’s instructions and used immediately.
  1.  Dilute the capture  antibody to the working concentration 
using PBS and coat a 96-well microplate with 100 μL per well. 
  2.  Seal the plate and incubate overnight at room temperature. 
  3.  Wash each well three times with 400 μL of wash buffer ( see 
 Note  9 ). 
  4.  Block the plate by adding 300 μL of reagent diluent to each 
well and incubate for 1 h at room temperature. Repeat the 
washing step as above. 
  5.  Add 100 μL of sample (it may be necessary to dilute the sam-
ples prior use) or standards in reagent diluent per well. Cover 
the plate with an adhesive strip and incubate overnight at 4 °C. 
  6.  Repeat the washing step as above. 
  7.  Add 100 μL of the diluted  detection  antibody to each well and 
incubate for 2 h at room temperature. 
  8.  Repeat the washing step as  above . 
3.4  Preparation 
of Neutrophil Lysates
3.5  Measurement 
of Intracellular  PTX3 
in Neutrophils 
by  ELISA 
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  9.  Add 100 μL of the working dilution of streptavidin- horseradish 
peroxidase (HRP) to each well. 
  10.  Seal the plate and incubate at room temperature for 20 min 
( see  Note  10 ). 
  11.  Repeat the washing step as above. 
  12.  Add 100 μL of substrate solution to each well and incubate at 
room temperature for 20 min ( see  Note  11 ). 
  13.  Add 50 μL of stop solution to each well and gently tap the 
plate to ensure thorough mixing. 
  14.  Determine the optical density of each well immediately using a 
microplate reader set to 450  nm ( see  Note  12 ). 
  1.  To estimate phagocytic activity, plate 5 × 10 5 freshly isolated 
neutrophils in 12 mm glass coverslips coated with serum pro-
teins or purifi ed fi brinogen in a 24-well plate. 
  2.  Add live FITC-labeled conidia of  A. fumigatus at an effector 
to fungal cell ratio of 1:5 in a fi nal volume of 500 μL 
( see  Note  13 ). 
  3.  Incubate at 37 °C for 1 h in a humidifi ed CO 2 culture 
chamber. 
  4.  After incubation, remove the non-adherent conidia by washing 
carefully twice with PBS. 
  5.  Add 300 μL of trypan blue (1 mg/mL in PBS) to each well for 
15 min at 25 °C to quench the fl uorescence of bound but 
uningested conidia. 
  6.  Wash twice with PBS and fi x the cells in 1 %  paraformaldehyde 
for 15 min. 
  7.  Mount coverslips with the cell side down onto microscope 
slides in 90 % glycerol in PBS, and seal with clear nail polish. 
  8.  Quantify phagocytosis via phase contrast and fl uorescence 
microscopy by counting at least 200 neutrophils per coverslip 
( see  Note  14 ). 
  1.  Incubate neutrophils with conidia of  A. fumigatus at an effec-
tor to fungal cell ratio of 10:1 for 120 min in a fi nal volume of 
100 μL in 96-well fl at-bottomed microtiter plates. 
  2.  After incubation, freeze plates at −80 °C and rapidly thaw at 
37 °C to lyse cells and harvest conidia. 
  3.  Prepare serial dilutions (1:10) from each well in PBS (900 μL) 
and plate 100 μL onto Sabouraud dextrose agar plates. 
  4.  Incubate plates at 28 °C for 48 h. 
  5.  Count the number of colony-forming units (CFU) and calcu-
late the percentage of CFU inhibition (referred to as the fun-
gicidal activity) ( see  Note  15 ). 
3.6  Measurement 
of Phagocytosis 
in Neutrophils
3.7  Evaluation 
of Neutrophil 
Fungicidal Activity
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4  Notes 
  1.  It is recommended to add β-mercaptoethanol to the genomic 
lysis buffer at a fi nal dilution of 0.5 % (v/v) to improve lysis 
performance. 
  2.  Ensure that the elution process occurs for at least 1 min to 
increase the DNA yield. 
  3.  The use of at least 20 ng of DNA in each genotyping reaction 
is recommended. Use an identical DNA concentration for all 
samples in order to adequately normalize the fl uorescence 
intensity. 
  4.  The thermal profi le presented is a typical example that has 
been specifi cally provided by the manufacturer with some 
minor modifi cations. Because of the underlying chemistry 
mechanisms of KASPar, the post-PCR read should always be 
performed below 40 °C. 
  5.  An optimal cluster visualization is typically obtained using a 
7500 Fast qPCR system (Applied Biosystems) and a post-PCR 
read at 25 ° C . 
  6.  Take care to preserve the interface between the Histopaque 
and the diluted blood solution, thereby avoiding  contamina-
tion between both phases. 
  7.  The temperature of 20 °C is crucial to achieve the best cell 
separation performance. 
  8.  After separation, cells should be kept on ice at all times and 
handled gently to prevent damage or undesired activation of 
neutrophils. 
  9.  Complete removal of liquid from the wells by inverting the 
plate and blotting it against clean paper towels is essential for 
an optimal performance of the  ELISA test. 
  10.  Avoid exposing the plate to light. 
  11.  The length of incubation may vary depending on the concen-
tration of  PTX3 . For that reason, check the plate every 5 min 
and stop the reaction earlier, if necessary. 
  12.  If wavelength correction is available, set it to 540 nm or 
570 nm. If wavelength correction is not available, subtract 
readings at 540 nm or 570 nm from the readings at 450 nm in 
order to correct for optical imperfections in the plate. 
  13.  For the staining of live conidia of  A. fumigatus , incubate 
2 × 10 7 conidia in 2 mL of Na 2 CO 3 50 mM buffer, pH  10.2 
with FITC at a fi nal concentration of 0.1 mg/mL (prepared in 
the same buffer) at 37 °C for 4 h. Wash the conidia thoroughly 
to eliminate residual FITC. 
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  14.  Enumerate the number of ingested conidia, or bound but not 
ingested. The data is typically presented as the percentage of 
neutrophils ingesting one or more conidia. 
  15.  Calculate the inhibition of CFU—also known as fungicidal 
activity—using the following formula: % fungicidal activ-
ity = (1− X / C ) × 100 where  X is the number of CFU obtained 
after infection of neutrophils, and  C is the number of CFU in 
the absence of neutrophils. Perform three biological replicates 
for each condition and at least two technical  replicates . 
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